Valor202020212022202320242025TTMGastos comerciales, generales y administrativos528.93 M619.92 M665.1 M747.86 M751 M743.07 M743.07 MInvestigación y desarrollo———————Beneficio operativo432.73 M589.86 M650.98 M617.26 M227.35 M25.16 M25.16 MTotal de ingresos no operativos197.55 M-60.87 M30.12 M97.58 M-12.92 M-22.02 M-22.02 MGastos por intereses, netos de intereses capitalizados86.43 M73.91 M59.29 M136.71 M126.29 M107.03 M107.03 MIngresos no operativos, una vez deducidos los gastos por intereses11.13 M-98.89 M-59.69 M-134.67 M-122.69 M-106.48 M-106.48 MIngresos/gastos extraordinarios99.98 M-35.89 M30.52 M95.54 M-16.52 M-22.58 M-22.58 MBeneficio antes de impuestos447.11 M480.71 M622.99 M581.28 M93.11 M-99.5 M95.09 MParticipación en los beneficios-27.6 M-40.2 M—————Impuestos81.81 M81.87 M130.38 M100.91 M67.82 M42.66 M42.66 MParticipación minoritaria1 M7.86 M6.38 M5.75 M3.09 M2.17 M2.17 MOtros ingresos/gastos después de impuestos-17.27 M-4.96 M-27.54 M-1.59 M-33.25 M-2.5 M-2.5 MBeneficio neto antes de actividades interrumpidas364.3 M390.98 M486.23 M474.62 M22.2 M-144.34 M-144.34 MOperaciones suspendidas0——————Beneficio neto364.3 M390.98 M486.23 M474.62 M22.2 M-144.34 M-144.34 MAjuste por dilución——00———Dividendos de las acciones preferentes——3.52 M-3.32 M———Beneficio neto diluido atribuible a los accionistas364.3 M390.98 M482.7 M477.94 M10.3 M-144.34 M-144.34 MBeneficio básico por acción7.357.779.579.270.2-2.91-2.91Beneficio por acción diluido7.27.69.489.220.2-2.91-2.91Número medio de acciones ordinarias49.55 M50.29 M50.81 M51.23 M51.38 M49.56 M198.6 MAcciones diluidas50.61 M51.42 M51.3 M51.45 M51.63 M49.56 M199.16 MEBITDA2.5 B3.09 B3.63 B3.56 B3.15 B2.79 B2.56 BEBIT2.26 B2.83 B3.33 B3.24 B2.79 B2.39 B2.16 BCosto de los ingresos————46.99 M12.44 M12.44 MOtros costes de producción————46.99 M12.44 M12.44 MAmortización y depreciación (flujo de caja)234.92 M265.54 M303.87 M314.12 M361.74 M403.31 M403.31 M
Charles River Laboratories International Inc
Charles River Laboratories International, Inc. is an American pharmaceutical and biotechnology contract research organisation headquartered in Wilmington, Massachusetts, United States. Founded in 1947, the company provides preclinical and clinical laboratory services for the development of new drugs, vaccines, and medical devices. Its operations span at least 20 countries, offering research models, safety assessment, and manufacturing support services to pharmaceutical, biotechnology, and government clients.
Charles River Laboratories is considered one of the largest CROs globally, known for its role in toxicology studies, animal research models, and microbial testing services used in regulatory submissions to health authorities such as the U.S. Food and Drug Administration. The company has also been the subject of public scrutiny and regulatory attention over its use of laboratory animals, including dogs, primates, and horseshoe crabs.
As of 2024, the company employs over 20,000 people worldwide and is publicly traded on the New York Stock Exchange under the ticker symbol CRL.